Company Performance Metrics
- Past Role: Polaris Genomics, CSO & Co-Founder
- Anne Naclerio: CMOPast Role: Polaris Genomics, Chief Medical Officer
Polaris Genomics is mapping molecular biomarkers to chart a new course for objective mental health diagnostics and novel therapeutics.
Polaris Genomics identifies genomic biomarkers to support the development of psychiatric drugs and clinical tools. The company's genomics-based ADAPT Platform™ curates information on biologically-relevant
gene network pathways indicated in neuropsychiatric conditions — including anxiety, depression, alcohol/substance use disorder, ADHD, PTSD, and TBI (ADAPT).
The ADAPT Platform™ comprises: 1. targeted neuropsychiatric gene panel, which contains 1000+ transcriptomic biomarkers related to known system pathways in neuropsychiatric conditions; 2. deep analytics (AI/ML) engine; and 3. expanding data lake and sample repository. ADAPT has identified transcriptomic biomarkers for PTSD, resulting in the first-of-its-kind clinical blood test for PTSD screening, Polaris' PTS-ID™.
